Search clinical trials for: LC51-0255

Total 85 results

LG Chem

Withdrawn

Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis

Ulcerative Colitis
LG Chem

Completed

A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255

Healthy

Korea, Republic of
Nurix Therapeutics, Inc.

Active, not recruiting

A Study of DeTIL-0255 in Adults With Advanced Malignancies

Cervical Cancer | Endometrial Cancer | Platinum-resistant Ovarian Cancer

United States
LG Life Sciences

Completed

Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444

Healthy

Korea, Republic of
Astria Therapeutics, Inc.

Completed

A Study of STAR-0215 in Healthy Adult Participants

Hereditary Angioedema

United States
GV20 Therapeutics

Recruiting

A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Cholangiocarcinoma | Non-small Cell Lung Cancer | Endometrial Carcinoma | Head and Neck Carcinoma | Cutaneous Melanoma | Solid Tumor, Adult | Refractory Cancer | Adenocarcinoma of the Rectum | Bladder Urothelial Carcinoma | Adenocarcinoma of the Colon

United States
Astria Therapeutics, Inc.

Recruiting

A Study of STAR-0215 in Participants With Hereditary Angioedema

Hereditary Angioedema

United States, United Kingdom, Canada, Germany, Bulgaria
Astria Therapeutics, Inc.

Enrolling by invitation

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Hereditary Angioedema

United States
Carisma Therapeutics Inc

Recruiting

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

HER2-positive

United States
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
LG Life Sciences

Completed

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
Foresee Pharmaceuticals Co., Ltd.

Completed

The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma

Asthma, COPD

Netherlands
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
China Medical University Hospital
Department of Health, Executive Yuan, R.O.C. (Taiwan)

Unknown

Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients

Breast Cancer | Leucopenia

Taiwan
AO GENERIUM

Recruiting

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
LG Life Sciences

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
jianming xu
KAEDI

Recruiting

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Solid Tumor | CRC

China
AO GENERIUM

Completed

A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Foresee Pharmaceuticals Co., Ltd.

Terminated

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Severe to Critical COVID 19 With Associated ARDS

United States
Biomedical Radiation Sciences
Swedish Cancer Society; Affibody

Completed

PET Study of Breast Cancer Patients Using [68Ga]ABY-025

Breast Cancer

Sweden
Foresee Pharmaceuticals Co., Ltd.
QPS-Qualitix

Completed

Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Healthy

Taiwan
Idera Pharmaceuticals, Inc.

Completed

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Renal Cell Carcinoma

United States
RasCal Therapeutics, Inc.

Recruiting

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Glioblastoma | Pancreatic Cancer | Lung Cancer | Colon Cancer | Advanced Malignant Solid Neoplasm | RAS Mutation

United States
Biomedical Radiation Sciences
Swedish Cancer Society

Completed

Exploratory Study of Breast Cancer With ABY025 (ABY0125)

Breast Cancer

Sweden
GlaxoSmithKline

Completed

An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

Malaria

Burkina Faso, Kenya, Tanzania
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
KAEDI

Not yet recruiting

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Glioma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor

China
Foresee Pharmaceuticals Co., Ltd.

Completed

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Healthy

Netherlands
Debiopharm International SA

Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Romania, Italy, Belgium, Germany, Hungary, Taiwan, Spain, Australia, Hong Kong, Thailand, France, United States, United Kingdom, Turkey, Argentina, Russian Federation, India, Korea, Republic of, Vietnam, Poland, Mexico, Canada
Plotnikoff, Gregory A., M.D.
University of Minnesota; Tsumura and Company, Tokyo, Japan

Completed

TU 025 Keishi Bukuryo Gan for Post-menopausal Hot Flash Management

Hot Flashes | Menopause

United States
Replicor Inc.

Completed

Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients

Hepatitis B, Chronic

Bangladesh
EMD Serono

Completed

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Non-Small Cell Lung Cancer

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Healthy

Belgium
Valneva Austria GmbH

Completed

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Dorte Nielsen

Terminated

HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025

HER2-positive Breast Cancer

Denmark
Waisenmedizin e. V. Promoting Access to Essential...
University of Freiburg; Waisenmedzin eV PACEM non-profit German NGO; German Medical... and other collaborators

Completed

Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul (rtt-ACL)

Wound Healing

Afghanistan
Biocad

Completed

Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

Russian Federation, Belarus
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
BioMarin Pharmaceutical

Recruiting

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

Nonalcoholic Fatty Liver Disease | Kidney Stone | Hyperoxaluria

United States
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
LG Life Sciences

Completed

Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Jiujiang University Affiliated Hospital
KAEDI

Withdrawn

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
Valneva Austria GmbH

Completed

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
EMD Serono

Terminated

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

Colorectal Cancer

United States
Valneva Austria GmbH

Completed

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Nektar Therapeutics

Completed

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Multiple Myeloma | Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma

United States
U.S. Army Medical Research and Development Command
Uniformed Services University of the Health Sciences; Meiji Seika Pharma Co...

No longer available

Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

Infection Due to Resistant Organism

United States
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
M.D. Anderson Cancer Center
Nektar Therapeutics

Recruiting

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Lung Cancer

United States

Search clinical trials for: LC51-0255

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations